Zealand Pharma A/S at Jefferies London Healthcare Conference Transcript
Thank you all for joining us. For those who don't know me, my name is Peter Welford. I'm one of the European pharma and biotech analysts at Jefferies in London. It's my great pleasure to be moderating the next session in this track, which is Zealand Pharma. And it's a pleasure to have with us here today, so it seems like a long way away.
But that is Adam Steensberg, who's the CEO of Zealand Pharma. It's a fireside format. So if anyone has any questions in the audience, and it might cool you down, apologies for the temperature by cooling down, if you have some questions. If anyone has any questions, please do raise your hand, we'd love to get some questions from the audience.
Questions & Answers
With that, let me kick off. So perhaps first of all, I guess it would probably make sense to just cover the sort of strategic changes that's happened in Zealand over the course of the last year or so. So could you just outline for us part, first of all,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |